比较新泽西州在治疗丙型肝炎感染的独特护理模式中使用的两种 DAAs。

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2024-11-27 eCollection Date: 2024-12-01 DOI:10.1093/ofid/ofae645

Jihad Slim, Paul Bellafiore, Barbara Tempalski, Corey Rosmarin-DeStefano, Kevin Leyden, Juan Torres, Sheena Duprey, Emily Levaggi

{"title":"比较新泽西州在治疗丙型肝炎感染的独特护理模式中使用的两种 DAAs。","authors":"Jihad Slim, Paul Bellafiore, Barbara Tempalski, Corey Rosmarin-DeStefano, Kevin Leyden, Juan Torres, Sheena Duprey, Emily Levaggi","doi":"10.1093/ofid/ofae645","DOIUrl":null,"url":null,"abstract":"In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 12","pages":"ofae645"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600950/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey.\",\"authors\":\"Jihad Slim, Paul Bellafiore, Barbara Tempalski, Corey Rosmarin-DeStefano, Kevin Leyden, Juan Torres, Sheena Duprey, Emily Levaggi\",\"doi\":\"10.1093/ofid/ofae645\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.\",\"PeriodicalId\":19517,\"journal\":{\"name\":\"Open Forum Infectious Diseases\",\"volume\":\"11 12\",\"pages\":\"ofae645\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600950/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Forum Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ofid/ofae645\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae645","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在这项前瞻性观察研究中，我们比较了 glecaprevir/pibrentasvir 与 sofosbuvir/velpatasvir 在治疗丙型肝炎方面的疗效，这种独特的治疗模式综合利用了远程医疗、流动车、个案管理和签约药房。在接受治疗的 769 名患者中，90.4% 的患者完成了治疗，9.6% 的患者失去了随访。两种治疗方案均显示出较高的完成率和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey.

In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.